Increased Usage of Carbapenems, Pfizer’s Tygacil and Colistin for Gram-Negative Infections Represents Shifts in Treatment to

  Increased Usage of Carbapenems, Pfizer’s Tygacil and Colistin for
  Gram-Negative Infections Represents Shifts in Treatment to Later-Lines of
  Therapies and to Reserved Antibiotics in Both U.S. and European Markets

       BioTrends Research Group and Arlington Medical Resources Release
            TreatmentTrends®: Gram-Negative Infections (EU) Report

Business Wire

EXTON, Pa. -- June 13, 2012

BioTrends Research Group and Arlington Medical Resources (AMR) in their
TreatmentTrends: Gram-Negative Infections (EU) report find that drug-resistant
and multi-drug resistant (MDR) Gram-negative (GN) pathogens, including
extended spectrum beta lactamase-producing pathogens, MDR Pseudomonas
aeruginosa and Acinetobacter species are on the rise in Europe. Moreover, the
study finds that the lack of effective treatment options for these infections
is driving increased prescribing of colistin, Pfizer’s Tygacil and
carbapenems, namely AstraZeneca’s Merrem (meropenem, generics), Merck’s
Primaxin (imipenem-cilastatin, generics) and Janssen’s Doribax (doripenem). In
fact, nearly 80 percent of surveyed physicians report increasing their usage
of colistin for Gram-negative infections (GNIs) and approximately half of
Tygacil users indicate prescribing more Tygacil for the treatment of
complicated intra-abdominal infections due to GN pathogens. Approximately,
one-third of infectious diseases specialists and one-fifth of critical
care/intensive care unit (ICU) specialists cite increased usage of the
carbapenems as the major treatment change for the management of GNIs in the
past five years.

“The rising rates of drug-resistance in GNIs in both the United States and
Europe and the uptake of drugs in the inpatient setting with noted safety
risks emphasizes the need for new therapies with efficacy in
difficult-to-treat GNIs, such as hospital-acquired pneumonia, and have a high
barrier to resistance development,” said Associate Therapeutic Class Director
of Infectious Diseases Brenda Perez-Cheeks, Ph.D.

For the management of P. aeruginosa infections, a majority of surveyed
physicians in Europe report prescribing a combination of two anti-pseudomonal
antibiotics with a preference for using an aminoglycoside as part of a
combination regimen. This is in contrast to BioTrends and AMR’s findings in
TreatmentTrends: Gram-Negative Infections (US), where combinations of two
beta-lactam antibiotics or a beta-lactam and a fluoroquinolone are the leading
therapies prescribed by U.S. physicians.

Physician perceptions of the carbapenems for the management of GNIs are highly
favorable and European physicians rate meropenem highest on performance in
GNIs as compared to other GN therapies. Although physicians are satisfied with
Doribax’s performance in GNIs, only 13 percent of surveyed physicians report
prescribing the drug in the past year.

With regard to awareness of therapies in development for the treatment of
GNIs, ID specialists report the greatest awareness with Basilea’s
ceftobiprole, whereas critical care/ICU specialists are most familiar with
Intercell’s P. aeruginosa vaccine candidate. Physicians cite a higher degree
of awareness of Cubist/Astellas’s CXA-201 and of Forest/AstraZeneca’s CEF-104
and CAZ-AVI versus other GNI products in the pipeline.

About TreatmentTrends

TreatmentTrends: Gram-Negative Infections (EU) is an annual report that
provides insight into the treatment of patients with Gram-negative infections
in the hospital setting. Research with 251 infectious diseases specialists and
critical care/ICU specialists analyzes the usage and uptake of antibiotics for
the treatment of key infections due to emerging and clinically important
Gram-negative pathogens in the EU5 markets. TreatmentTrends is a syndicated
report series that provides longitudinal information on market dynamics,
including insight into practice patterns, attitudes and perceptions, unmet
needs, and projected and current use of antibiotics in the hospital.
TreatmentTrends: Gram-Negative Infections (US), the companion study, tracking
the usage of antibiotics in the U.S. to treat these infections, was published
on April 2012.

About BioTrends Research Group

BioTrends Research Group provides syndicated and custom market research to
pharmaceutical manufacturers competing in clinically evolving, specialty
pharmaceutical markets. For information on BioTrends publications and research
capabilities, please contact us at (610) 321-9400 or
BioTrends is a Decision Resources Group company.

About Arlington Medical Resources

AMR ( serves the market intelligence needs of the
pharmaceutical and diagnostic imaging industries. Research includes clinical
inpatient databases that directly link anti-infective drugs with
indication/procedure, formulary and stocking status tracking studies, drug
purchasing audits and diagnostic imaging procedure volume/contrast media usage
audits. AMR is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group

    All company, brand, or product names contained in this document may be
                   trademarks of their respective holders.


BioTrends Research Group, LLC
Brenda Perez-Cheeks, Ph.D., 610-908-7255
Decision Resources Group
Lisa Osgood, 781-993-2606
Press spacebar to pause and continue. Press esc to stop.